Swoboda, David M. http://orcid.org/0000-0002-6102-1695
Kanagal-Shamanna, Rashmi http://orcid.org/0000-0001-7829-5249
Brunner, Andrew M.
Cluzeau, Thomas http://orcid.org/0000-0002-6745-1127
Chan, Onyee http://orcid.org/0000-0003-2872-1961
Al Ali, Najla
Montalban-Bravo, Guillermo
Gesiotto, Quinto J.
Gavralidis, Alexander
Hunter, Anthony M.
Lee, Jung-Hoon http://orcid.org/0000-0003-3683-9468
Kuykendall, Andrew T.
Talati, Chetasi http://orcid.org/0000-0002-2246-213X
Sweet, Kendra L.
Lancet, Jeffrey E. http://orcid.org/0000-0002-7751-7310
Padron, Eric http://orcid.org/0000-0002-4707-7916
Hussaini, Mohammad
Song, Jinming
Garcia-Manero, Guillermo http://orcid.org/0000-0002-3631-2482
Komrokji, Rami S. http://orcid.org/0000-0002-1876-5269
Sallman, David A. http://orcid.org/0000-0003-0504-8233
Article History
Received: 27 July 2021
Revised: 8 November 2021
Accepted: 18 November 2021
First Online: 3 January 2022
Competing interests
: DMS, RKS, TC, OC, NAA, GMB, QJG, AG, AMH, JL, JS, and GGM declare no conflict of interest. AMB has done consulting for Novartis, BMS, Agios, Acceleron, and Takeda. ATK has done consulting for Abbvie, Blueprint, Celgene/BMS, Incyte, Novartis, PharmaEssentia, Protagonist, CTI Biopharma and has been part of a speaker’s bureau for Blueprint and Novartis. He receives research support from Sierra, Protagonist, and Prelude. CT is on advisory boards for Abbvie, BMS, Celgene, Daiichi Sankyo, Pfizer, and Novartis and has been part of a speaker’s bureau for Astellas, BMS, and Jazz. KS is on advisory committees for Arog, BMS, Gilead and Novartis. She has received research funding from Incyte and has received Honoraria from Stemline and Astellas. JEL has done consulting for AbbVie, Agios, Astella, Daiichi Sankyo, ElevateBio, Jazz, and Takeda and received Honoria from Agios. EP obtains research funding from Incyte, Kura Oncology, and BMS and has received Honoraria from Taiho. MH has done consulting and received honoraria from Adaptive Biotechnology, Stemline, Amgen, Seattle Genetics, BMS, Boston Biomedical, Decibio, Wells Fargo, Pivot and Blueprint Medicine. GGM RSK has been part of a speaker’s bureau for Jazz and BMS and received honoraria from JAZZ, BMS, Abbvie, Acceleron, Novartis, and Geron. DAS has received research funding from Aprea and Jazz, done consulting for AbbVie, Agios, Aprea, BMS, Incyte, Intellia, Kite, Magenta, Novartis, Shattuck Labs, and Takeda and part of a speaker’s bureau for BMS, Incyte. None of these relationships were related to the development of this manuscript.